121 related articles for article (PubMed ID: 24508830)
1. Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: toward the discovery of novel Akt1 inhibitors.
Zhan W; Li D; Che J; Zhang L; Yang B; Hu Y; Liu T; Dong X
Eur J Med Chem; 2014 Mar; 75():11-20. PubMed ID: 24508830
[TBL] [Abstract][Full Text] [Related]
2. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
3. Integrating docking scores and key interaction profiles to improve the accuracy of molecular docking: towards novel B-Raf
Hu CQ; Li K; Yao TT; Hu YZ; Ying HZ; Dong XW
Medchemcomm; 2017 Sep; 8(9):1835-1844. PubMed ID: 30108894
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation, and molecular docking of novel benzopyran and phenylpyrazole derivatives as Akt inhibitors.
Zhan W; Lin S; Chen J; Dong X; Chu J; Du W
Chem Biol Drug Des; 2015 Jun; 85(6):770-9. PubMed ID: 25453512
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.
Liu T; Zhan W; Wang Y; Zhang L; Yang B; Dong X; Hu Y
Eur J Med Chem; 2014 Feb; 73():167-76. PubMed ID: 24389511
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of novel Akt1 inhibitors based on an indole scaffold.
Yang D; Tong D; Zhang Q; Wang Y; Sun J; Zhang F; Zhao G
Chem Biol Drug Des; 2017 Nov; 90(5):791-803. PubMed ID: 28390089
[TBL] [Abstract][Full Text] [Related]
8. QSAR study of Akt/protein kinase B (PKB) inhibitors using support vector machine.
Dong X; Jiang C; Hu H; Yan J; Chen J; Hu Y
Eur J Med Chem; 2009 Oct; 44(10):4090-7. PubMed ID: 19497644
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors.
Ajmani S; Agrawal A; Kulkarni SA
J Mol Graph Model; 2010 Apr; 28(7):683-94. PubMed ID: 20153226
[TBL] [Abstract][Full Text] [Related]
10. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery.
Halder AK; Cordeiro MNDS
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920446
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics simulation study and molecular docking descriptors in structure-based QSAR on acetylcholinesterase (AChE) inhibitors.
Gharaghani S; Khayamian T; Ebrahimi M
SAR QSAR Environ Res; 2013; 24(9):773-94. PubMed ID: 23863115
[TBL] [Abstract][Full Text] [Related]
12. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors.
Dong X; Zhou X; Jing H; Chen J; Liu T; Yang B; He Q; Hu Y
Eur J Med Chem; 2011 Dec; 46(12):5949-58. PubMed ID: 22027102
[TBL] [Abstract][Full Text] [Related]
14. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
Falchi F; Manetti F; Carraro F; Naldini A; Maga G; Crespan E; Schenone S; Bruno O; Brullo C; Botta M
ChemMedChem; 2009 Jun; 4(6):976-87. PubMed ID: 19326384
[TBL] [Abstract][Full Text] [Related]
15. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
[TBL] [Abstract][Full Text] [Related]
16. Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor.
Al-Sha'er MA; Taha MO
J Mol Graph Model; 2018 Aug; 83():153-166. PubMed ID: 29456101
[TBL] [Abstract][Full Text] [Related]
17. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
Wu K; Ai J; Liu Q; Chen T; Zhao A; Peng X; Wang Y; Ji Y; Yao Q; Xu Y; Geng M; Zhang A
Bioorg Med Chem Lett; 2012 Oct; 22(20):6368-72. PubMed ID: 22985853
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III.
Xu F; Xu H; Wang X; Zhang L; Wen Q; Zhang Y; Xu W
Bioorg Med Chem; 2014 Feb; 22(4):1487-95. PubMed ID: 24440479
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure based optimization of novel Akt inhibitors.
Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
[TBL] [Abstract][Full Text] [Related]
20. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.
Mahajan P; Wadhwa B; Barik MR; Malik F; Nargotra A
Mol Divers; 2020 Feb; 24(1):45-60. PubMed ID: 30798436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
